Parkinsonism-Hyperpyrexia Syndrome Treatment
Immediately reinstitute antiparkinsonian medications at their previous doses—this is the cornerstone of treatment and directly addresses the underlying hypodopaminergic crisis that defines this syndrome.
Understanding the Condition
Parkinsonism-hyperpyrexia syndrome (PHS) is a life-threatening neurological emergency caused by acute dopamine depletion in the central nervous system, typically triggered by abrupt withdrawal or significant dose reduction of antiparkinsonian medications 1, 2, 3, 4. The syndrome presents identically to neuroleptic malignant syndrome (NMS) with the tetrad of altered mental status, hyperthermia, severe rigidity, and autonomic instability 5.
Immediate Management Algorithm
1. Medication Reinstitution (Primary Treatment)
- Restart all antiparkinsonian medications immediately at their previous therapeutic doses
- If oral administration is impossible due to altered consciousness or dysphagia, use alternative routes:
The literature consistently demonstrates that prompt medication reinstitution leads to gradual symptom resolution 1, 2, 3, 4. Recovery typically occurs over days to weeks, with PHS showing different recovery kinetics than dyskinesia-hyperpyrexia syndrome 3.
2. Dopaminergic Augmentation
Add bromocriptine (a dopamine agonist) if fever persists despite restarting usual medications 1:
- This provides additional dopaminergic support during the acute crisis
- Particularly useful when oral levodopa absorption may be compromised
3. Supportive Care Measures
Hyperthermia management:
- Administer 2000-3000 mL chilled (4°C) 0.9% saline intravenously
- Apply surface cooling: wet cold sheets, fans, ice packs to axillae and groin
- Stop cooling once temperature drops below 38.5°C 8
- Note: Antipyretics are typically ineffective because fever results from muscular hyperactivity, not hypothalamic set-point changes 5
Control extreme muscle activity:
- Benzodiazepines for moderate cases to reduce rigidity and agitation 5
- In severe cases requiring paralysis, use nondepolarizing agents only (vecuronium or rocuronium)
- Avoid succinylcholine due to risk of hyperkalemia and worsening rhabdomyolysis 5
4. Intensive Monitoring
Transfer to ICU for close observation 2:
- Continuous cardiac monitoring (ECG)
- Core temperature monitoring
- Establish wide-bore IV access
- Consider arterial line and central venous access
- Insert urinary catheter
Laboratory surveillance:
- Creatine kinase (typically markedly elevated in PHS) 1, 4
- Electrolytes, particularly potassium
- Renal function (creatinine, BUN)
- Liver enzymes (transaminases may be elevated) 1
- Arterial blood gases
- Myoglobin levels
- Monitor for compartment syndrome
5. Manage Complications
Rhabdomyolysis and renal protection:
- Maintain urine output >2 mL/kg/hour
- Furosemide 0.5-1 mg/kg
- Mannitol 1 g/kg
- Aggressive IV crystalloid hydration 8
Treat hyperkalemia if present:
- Dextrose 50%, 50 mL with 50 IU insulin (adult dose)
- Calcium chloride 0.1 mmol/kg IV
- Dialysis may be required in severe cases 8
Manage autonomic instability:
- For fluctuating blood pressure: use short-acting agents (esmolol, nitroprusside)
- Use direct-acting sympathomimetics (phenylephrine, norepinephrine, epinephrine) rather than indirect agents like dopamine 5
- For persistent tachycardia after addressing hyperthermia: consider beta-blockers 8
Critical Distinctions and Pitfalls
Differentiate PHS from other hyperthermic syndromes:
- PHS trigger: Medication withdrawal/reduction in known PD patients
- NMS trigger: Dopamine antagonist exposure (antipsychotics)
- Malignant hyperthermia: Volatile anesthetics or succinylcholine exposure during surgery 8
- Serotonin syndrome: Serotonergic medication exposure
The key distinguishing feature is the medication history in a patient with established Parkinson's disease 2, 3, 4.
Common precipitants to recognize:
- Perioperative NPO status causing medication interruption 2, 9
- Patient noncompliance with medications 1
- DBS battery depletion or system malfunction 6, 7
- Acute medical illness preventing medication intake
Mortality considerations: Literature reviews show similar mortality rates between PHS and dyskinesia-hyperpyrexia syndrome, emphasizing the life-threatening nature of this condition 3. Early recognition and immediate treatment are essential to reduce mortality 3, 4.
Perioperative Prevention
For PD patients undergoing surgery 2, 9:
- Never allow complete interruption of antiparkinsonian medications
- Arrange alternative administration routes preoperatively (NG tube, transdermal)
- Maintain DBS function throughout the perioperative period
- Monitor closely for early withdrawal symptoms (tremor worsening, rigidity, autonomic changes)
The fundamental principle is that PHS represents an acute dopaminergic crisis requiring immediate dopamine replacement—delays in medication reinstitution directly correlate with worse outcomes.